analysts and calls -- ML | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
analysts and calls -- ML

An SI Board Since September 2002

Posts	SubjectMarks	Bans
238	19	0

Emcee: scaram(o)uche	Type: Moderated

Introduction Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
63	part 2 spending, increased discounting by J&J/Amgen in the EPO market, a ne	tom pope	-	11/12/2003
62	Biotech, part 1. 10. 5 Biotechnology Supply/Demand Imbalance Hurting Sector Typ	tom pope	-	11/12/2003
61	VRTX: Highlights: • VRTX reported financial results for Q3/03 on November 10, 2	tom pope	-	11/11/2003
60	Here are the estimates: Price: $57.42 Price Objectve $69.00 Price Objective Dat	tom pope	-	10/29/2003
59	GILD has been an Ende favorite for some time Earnings Analysis; Weak Reported	tom pope	-	10/29/2003
58	IVX IVAX Corp Company Update; A Strong 2004 may be in Store While we believe	tom pope	-	10/28/2003
57	ABGX, I'm afraid I missed this one when it came out on 10/21: Highlights: •	tom pope	-	10/23/2003
56	Genzyme Corp Resuming Coverage; Diverse Products, Two New Drugs, and a Simplif	tom pope	-	10/22/2003
55	Amgen Inc Earnings Analysis; Reports Strong 3Q03; Raising ’03, ’04 & ’05 E	tom pope	-	10/22/2003
54	Small cap - MOGN, NPSP and OSIP are all around $1bn, or close. If ML really want	tom pope	-	10/21/2003
53	07:03 ET [Oct 21] Early Research Calls ... Merrill Lynch out with a note cal	Doc Bones	-	10/21/2003
52	ML this morning: Alkermes Inc. Upgrading to BUY; Upgrading to BUY Based On Up	tom pope	-	10/10/2003
51	From ML Specialty Pharmaceuticals 3Q Preview With a few exceptions, we expect t	tom pope	-	10/7/2003
50	GILD Gilead Sciences Inc Update; Plenty of Upside Left For Viread; Raising Es	tom pope	-	10/2/2003
49	NPSP ASBMR 2003 PaTH Data Increases Probability of Success in Phase III Study T	tom pope	-	9/22/2003
48	Trying to beat Erik to the punch this time <g> Anti-depressants make up 80	tom pope	-	9/19/2003
47	Thanks, Erik, I've been asleep at the switch. <i>NPS Pharmaceuticals	tom pope	-	9/17/2003
46	7:57AM NPS Pharm target raised to $46 at Merrill Lynch (NPSP) 30.90: Merrill Lyn	Icebrg	-	9/17/2003
45	missed this yesterday MGI Pharmaceuticals (MOGN; $38.96; C-1-9) Initiating Cove	tom pope	-	8/21/2003
44	ML on NPSP NPS Pharmaceuticals (NPSP; $23.24; C-1-9) Comment Available Forteo S	tom pope	-	8/14/2003
43	ML still banging the GILD drum Gilead Sciences (GILD; $68.23; C-1-9) " Noi	tom pope	-	8/5/2003
42	and finally, BGEN Biogen Inc. (BGEN; $41.18; C-2-9) Avonex Higher; Amevive Lowe	tom pope	-	7/25/2003
41	NBIX Neurocrine Bioscience Inc. (NBIX; $53.30; C-2-9) Indiplon Data and FDA Fil	tom pope	-	7/25/2003
40	#2, MEDI: MedImmune Inc. (MEDI; $40.10; C-1- 9) 2Q03 EPS $0.06; Strong Synagis	tom pope	-	7/25/2003
39	ML has been busy today. #1, GILD: Gilead Sciences Inc (GILD; $66.10; C- 1-9) E	tom pope	-	7/25/2003

Go to reply# or date (mm/dd/yy):